药明系再扩产能,溢价一倍收购上市药企

健识局
Jan 15

1月14日晚,药明系几家上市公司抛出一份联合公告:药明合联以现金每股4港元的价格,向东曜药业提出全面收购要约。这是资本市场上很罕见的一家上市公司完全“吃下”另一家上市公司。东曜药业已发行股份约7.73亿股,股本总价值为30.91亿港元(约合人民币27.63亿元),要约最高代价约为27.9亿港元。根据公告,药明合联抛出的收购价,较股份不受干扰日,即2025年12月22日东曜药业收盘价每股2.01港元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10